Recent News

We continue working to develop and obtain the Food and Drug Administration (FDA) authorization to market potentially reduced risk tobacco products and provide truthful and accurate communications about them to adult tobacco consumers.

In support of this work we regularly engage with the scientific, public health, and regulatory communities through face-to-face meetings, regulatory filings, publishing in scientific journals and participating at scientific conferences where we present our research. We listen to and welcome feedback on our work.

We are always interested in hearing from other scientists and stakeholders. If you have questions, would like to provide feedback on our work, or learn more about our research and our approach to harm reduction, contact us today.

View to learn about the importance of engagement in helping to create the conditions for harm reduction to succeed in the U.S.

Advancing Harm Reduction: Altria Scientists Present at the 2024 CORESTA Congress

Discover the latest findings from Altria scientists at the 2024 CORESTA Congress in Scotland, where they presented research on the role of smoke-free products in promoting harm reduction.

Explore their Research

Insights from the 2024 FDLI Science Symposium & Policy Conference

Our team shared insights into the challenges and opportunities in tobacco regulation and policy, including the need for FDA authorization of smoke-free products, the role of flavors and tackling the illicit market for tobacco products.

Learn More

Illicit E-Vapor Products Widely Mislabel their Nicotine Composition

To better understand and evaluate the illicit market, Altria commissioned independent labs to analyze leading illicit e-vapor brands, which found a failure of consumer protection.

View Findings

Sharing our research at the 2024 Tobacco Science Research Conference

During the three-day conference, our scientists showcased their collective expertise and shared science supporting the role of smoke-free products in advancing harm reduction.

Sharing the Science at 2024 Conferences

Explore how we’re engaging externally in 2024 and hear from Greg on the importance of creating the conditions for long-term leadership and harm reduction in the tobacco industry.

Watch Video

Dr. Vergara presents at the 2024 Next Generation Nicotine Delivery USA Conference

Dr. Vergara's presentation highlighted the importance of non-combustible products, specifically NJOY ACE^®, in helping adults who smoke transition to reduced harm alternatives.

Dr. Hong presents at the 2024 Next Generation Nicotine Delivery USA Conference

During his presentation, Dr. Hong discussed the harm reduction opportunity in the U.S. for the heated tobacco product, Ploom^®.

2023 Global Tobacco and Nicotine Forum

Hear from Brent as he sheds light on the challenges adult tobacco consumers face in making informed choices and the need for accurate information and smoke-free options.

Watch Video

Global Forum on Nicotine – GFN Fives

We’re working hard to overcome nicotine misperceptions and other barriers to accelerating tobacco harm reduction. In 2023, we prepared a short video for the Global Forum on Nicotine addressing these barriers.

Watch Video

The Forgotten Smoker

Brent shared a video at the 2023 Global Forum on Nicotine around the forgotten smoker. Based on his ethnographic consumer research study, learn about the forgotten smokers' motivations for switching, barriers on the journey, and how we can better support them.

Watch Video

Tobacco Merchants Association 2023

To kick off the 2023 Tobacco Merchants Association Annual Meeting, Dr. Hannel joined a panel to discuss nicotine misperceptions and harm reduction. Dr. Hannel shared results of a model based on data from the Population Assessment of Tobacco and Health (PATH) Study.

FDLI’s 2023 Annual Meeting

Dr. Sarkar participated on a panel at the Food & Drug Law Institute’s (FDLI) Annual Conference on the role oral tobacco products can play in advancing harm reduction for adults who smoke.

Learn More